We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Foreign stocks · NYSE · Healthcare · Life sciences tools and technology
Held by 8 funds8 open to buy3 AMCs
Last close (USD)226.34−8.59 (−3.66%)as of 5 Nov 2026
Funds that hold it8One fund per scheme
Held through a master fund80 buy the stock themselves
Largest weight in a single fund2.96%Of that fund's NAV
Median weight2.90%Half the funds hold more than this
What does DHR do
Danaher Corp
Makes instruments, reagents and software for life science research, biopharmaceutical production and diagnostic labs worldwide
CepheidBeckman CoulterLeica BiosystemsCytivaPall
Where the revenue comes from, and how much is left as profit (FY2025)
For every 100 dollars of sales: cost of sales 41 · operating expenses 40 · tax and other items 4 · leaving 15 as net profit
Which funds let you invest in DHR
Sorted by weight held, largest first
Investors in Thailand can buy DHR through 8 mutual funds open to retail investors. Most of them (8 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds DHR.
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
KASSET
How Thai money reaches DHR
3 master funds
Master fund
Thai funds using this route
Master fund's DHR weight
JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
3
2.96%
JPMorgan Funds - Global Healthcare Fund
3
2.89%
VanEck Morningstar Wide Moat ETF
2
2.92%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Revenue by business segment: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
K Global Healthcare Equity RMF
2.96%
Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
+23.58%
Showing 8 of 8 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Valuation and key ratios
Danaher Corp · NYSE · Fiscal year ends in January
Market cap159.1B USD0.70 billion shares
P/E44.8xPrice ÷ FY2025 EPS 5.05
Forward P/E25.1xBased on forecast 12-month earnings
P/S6.5x
EV/EBITDA23.8x
Dividend yield0.67%1.52 USD per share a year
ROE7.1%Net profit ÷ shareholders' equity
Debt to equity (D/E)0.35xInterest-bearing debt
Beta0.77Against the S&P 500
Gross margin59.1%FY2025
Operating margin19.1%FY2025
Net margin14.7%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth−0.2%Slow growth
Yearly average over the last 4 years · Latest annual sales 24.6B USD
Profit from sales15%Moderate
For every 100 dollars of sales, about 15 dollars is left as net profit
Dividend0.67%Pays dividends
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+6.7%Up
Now 6.5% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows −0.2% a year on average · EPS grows −12.5% a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY202124.8B USD6.4B USD
FY202226.6B USD7.2B USD
FY202323.9B USD4.8B USD
FY202423.9B USD3.9B USD
FY202524.6B USD3.6B USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY20255.9B USD555.0M USD
Q3 FY20256.1B USD908.0M USD
Q4 FY20256.8B USD1.2B USD
Q1 FY20266.0B USD1.0B USD
Q2 FY20266.3B USD870.0M USD
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
24.8B USD
26.6B USD
23.9B USD
23.9B USD
24.6B USD
Gross profit
15.2B USD
16.2B USD
14.0B USD
14.2B USD
14.5B USD
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 226.34 USD on 5 Nov 2026
Daily trendSidewaysScore 0.10 on a scale of −1 to +1 · 1254 bars
RSI(14)
49.7
ADX(14)
32.6
Position in the price range
72%
Weekly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 261 bars
RSI(14)
59.0
ADX(14)
18.6
Position in the price range
80%
Monthly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 61 bars
RSI(14)
54.1
ADX(14)
22.5
Position in the price range
54%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
231.81
230.48
Below
20 days
228.97
228.42
Below
50 days
219.93
221.03
Above
100 days
208.73
212.72
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
49.68
Down
MACD(12,26)
3.30
Up
ADX(14)
32.63
Neutral
ATR(14) % of price
1.62
Neutral
Support and resistance (weekly pivots)
s3223
s2227
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
+23.58%
1.76%
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in DHR, not the look-through weight · Past performance is not a guarantee of future performance